RETRACTED: Chemokine profiles in blood associated with delayed asthmatic response to allergen challenge  by Pelikan, Zdenek
Respiratory Medicine (2013) 107, 47e59Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate/rmedChemokine profiles in blood associated
with delayed asthmatic response to
allergen challenge DZdenek Pelikan*Allergy Research Foundation, Effenseweg 42, 4838 BB Breda, The Netherlands
Received 21 July 2012; accepted 18 September 2012
Available online 30 October 2012 TE
KEYWORDS
Allergic bronchial
asthma;
Bronchial provocation
tests;
Delayed asthmatic
response;
Chemokines in
peripheral bloodR
* Tel.: þ31 76 522 30 74; fax: þ31 7
E-mail address: zpelikan@casema.
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.201Summary
Background: Patients with bronchial asthma having been challenged with allergen develop
various types of asthmatic response, such as immediate (IAR), late (LAR) or delayed (DYAR)
response, due to different immunologic mechanisms. The DYAR, beginning 26e32 h, reaching
maximum between 32 and 48 h and resolving within 56 h after the challenge, differs from IAR
and LAR in clinical and immunologic features.
Objectives: To investigate the changes in the serum concentrations of chemokines associated
with the isolated form of DYAR.
Methods: In 22 patients the repeated DYAR (p < 0.001) was supplemented with recording of
blood cell counts and serum concentrations of chemokines before, and up to 72 h after the
bronchial challenge by means of enzyme-linked immunoassay, (ELISA).
Results: The DYAR was associated with (a) significantly increased serum concentrations
(p < 0.05) of CCL 2, CCL 3, CCL 4, CCL 7, CCL 20, CXCL 1, CXCL 8, CXCL 9, CXCL 10 and CXCL
11, and (b) significantly decreased serum concentrations, (p < 0.05) of CCL 5, CCL 11, CCL 17,
CCL 22, CCL 24 and CCL 26, as compared with their pre-challenge as well as the PBS control
values. No significant chemokine changes were recorded during the PBS controls (p > 0.1).
Conclusions: These results, together with changes in the blood cell counts, provide evidence
for an involvement of activated Th1, cells and NK cells (CCL-2, -3, -4, -20, CXCL-9,-10,-11),
neutrophils (CCL-20, CXCL-1,-8) and monocytes (CCL-2,-3,-4, -7, CXCL-10), upon co-
operation of other cell types, such as epithelial, endothelial and dendritic cells, in the immu-
nologic mechanism(s) underlying the DYAR.
ª 2012 Elsevier Ltd. All rights reserved.
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Various immunologic mechanisms can be involved in various
clinical phenotypes of allergic bronchial asthma.1e6 Besides
the already established classic immediate hypersensitivity
based upon participation of IgE antibodies, mast cells/
basophils, eosinophils and Th2-lymphocytes, other hyper-
sensitivity mechanisms can also play a role in this con-
dition.1e15 Patients with bronchial asthma develop various
types of asthmatic response to bronchial allergen chal-
lenge, such as immediate (IAR),late (LAR) or a dual late
(DLAR; a combination of an immediate and a late) asth-
matic response. The IAR, LAR and DLAR have already been
extensively studied from various points of view.5,12,16e28
Some patients with bronchial asthma, examined at our
clinic, developed an asthmatic response appearing 26e56 h
after the bronchial challenge with various inhalant
allergens.29e32 This response phenotype, designated by us
as “delayed asthmatic response” (DYAR), displayed clinical
and immunologic features different from those associated
with the IAR and the LAR.2,3,5e12,19,21,25e28
The key clinical aspect of the DYAR was it onset later
than 26 h after the allergen exposure,29e32 whereas the
most important immunologic feature seems the predomi-
nant role of activated Th1 ecells, neutrophils and mono-
cytes in the mechanism(s) underlying the DYAR.29e32 The
DYAR was associated with increased counts of total leuko-
cytes, lymphocytes, neutrophils and shifting of the Th1/Th2
ratio in favor of Th1 cells in peripheral blood,
29e32
increased intracellular concentrations of IFN-g and IL-2,
but not of IL-4 or IL-5, in PBMC,29 increased serum
concentrations of sICAM-1, sVCAM-1, sPECAM-1, sE- and sL-
selectins, whereas decreased concentration of sE-Figure 1 The initial and repeated delayed asthmatic response to
control challenge. The mean percentage changes in the FEV1 value
DYARs and 22 PBS control challenges; (,)Z initial DYAR; (-)Z re
(baseline) values; ALL Z allergen challenge; PBS Z phosphate
line Z statistically significant decrease of FEV1 values (>20%).
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Acadherin,30 increased plasma concentrations of LTB4 and
MPO,31 and increased serum concentrations of some cyto-
kines, such as IFN-g, IL-2, IL-18, G-CSF, TNF-a and TGF-b.32
The purpose of this study was to search for the possible
changes in concentrations of other important components
of immunologic system, the particular chemokines, in
peripheral blood during the DYAR and in this way to
contribute not only to assessment of the role of individual
cell types in the DYAR, but also to the clarification of the
immunologic mechanism(s) underlying this response type.Methods
Patients
Some of bronchial asthma patients referred to our
Department of Allergology &Immunology, Inst. Med. Sci. De
Klokkenberg, Breda, The Netherlands, for more extensive
diagnostic and therapeutic analysis have developed an
isolated form of delayed asthmatic response (DYAR),
appearing later than 24 h after the bronchial challenge
with allergen (BPT, Fig.1). Twenty-two patients developing
the DYAR have volunteered to participate in this study
(Table 1).
These patients, 19e43 years of age, suffering from
reversible bronchial constriction, alternating with
symptom-free periods, showed pulmonary function without
any restrictive changes (GINA).33 They did not suffer from
current airway infections and did not use oral corticoste-
roids or receive immunotherapy. They were examined by
routine diagnostic procedure, serving also as an exclusion
criteria, consisting of a number of diagnostic parameters
TE
Dallergen challenge (DYAR) and phosphate buffered saline (PBS)
s with respect to the baseline values were calculated from 22
peated DYAR; (*)Z initial PBS; ()Z repeated PBS. IZ initial
buffered saline; Bars Z means  SEM; Dashed horizontal
C
Delayed asthmatic response and chemokines 49and including also 53 BPTs with allergens and 22 PBS control
challenges (Tables 1 and 2). All BPTs were performed under
standard and controlled conditions in a period without
manifest bronchial complaints and during hospitalization of
the patients.
Inhalation glucocorticosteroids (nZ 11) and long-acting
b2-sympathomimetics (n Z 9) were withdrawn 4 weeks
prior to BPTs, disodium cromoglycate (n Z 5), nedocromil
sodium (n Z 6) 2 weeks before challenges and other drugs
48 h prior to BPTs. If the post-challenge FEV1 or both FEV1
and FVC values decreased by 50% or more, with respect to
the predicted values, the patients (n Z 3) were treated
with a single dose of 400 mcg aerosolized salbutamol.
The supplementary parameters and the chemokine array
were determined in all patients studied and in control
subjects as a single test during the routine procedure
(Tables 1 and 3).
The BPTs with the inhalant allergens producing the DYAR
(n Z 22) (Table 2) and the PBS control challenges (n Z 22)
were repeated 3e4 weeks later (Fig. 1) and supplemented
with recording of cell counts and chemokines in theTable 1 Characteristics of the patients and control subjects.
Patients DYAR n Z 22 Cont
Patie
IAR n
Age (years) 33  5 28 
Gender (M/F) 10/12 5/4
Disease history (years) 4.3  2.5 4.8 
Asthmatic attacks per month 2  1 4 
FEV1 (% predicted) 94.5  7.2 95.4
FVC (% predicted) 97.6  6.4 98.3
Blood leukocyte count (x 109/L)a 11.2  0.6 6.9 
Blood neutrophil count (x 109/L)b 7.6  1.6 6.7 
Blood eosinophil count (x 106/L)c 314  27 463
Skin prick tests response
-immediate 7 9
Intracutaneous tests response
-immediate 9 8
-late 3 1
-delayed 10 0
Bronchial histamine thresholdd
2.0 mg/mL 0 1
4.0 mg/mL 2 3
8.0 mg/ml 2 1
16.0 mg/mL 10 2
32.0 mg/mL 3 2
>32.0 mg/mL 5 0
Ratio Th1/Th2 (%) in blood
e 8.2  2.5 7.3 
IFN-g (pg/mL)ePBMCf 194  61 155
IL-4 (pg/mL)ePBMCf 18.0  5.4 22.3
DYARZ delayed asthmatic response; IARZ immediate asthmatic resp
response (a combination of an immediate and a late response); Value
control subjects Z *p < 0.05 (in bold).
a Normal value Z 4.0e10  109/L.
b Normal value Z 2.0e7.2  109/L.
c Normal value Z <300  106/L.
d Normal value >32.0 mg/mL.
e Determined by means of flow-cytometry after stimulation with PM
f Determined by means of ELISA after “in vitro” stimulation of peri
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Aperipheral blood before, and 1, 12, 24, 36, 48, 56 and 72 h
after the challenge (Tables 4 and 5). The local ethics
committee (IRB-MCK) approved this study and a written
informed consent has been obtained from all participants.
The study has been carried out according to the WMA
Declaration of Helsinki concerning the Principles for
medical research involving the human subjects.
Control subjects
Thirty-five control subjects volunteered to participate in
this study; 9 asthmatics demonstrating an isolated IAR to
allergen challenge, 8 asthmatics developing an isolated
LAR, 6 asthmatics showing DLAR and 12 healthy subjects
(Table 1).
Allergens
Dialyzed and lyophilized allergen extracts (Allergopharma,
Reinbek, Germany) diluted in PBS were used inD
rol subjects
nts with asthma Healthy subjects n Z 12
Z 9 LAR n Z 8 DLAR n Z 6
3 31  2 29  3 32  6
4/4 2/4 5/7
2.4 5.1  1.6 5.0  1.9 0
1 3  1 3  2 0
 5.1 90.9  5.4 92.7  4.5 98.8  3.1
 3.9 99.4  4.7 101.1  3.9 103.2  6.0
0.7 8.1  1.2 8.8  0.9 6.3  0.8
1.3 5.9  2.4 6.3  1.5 6.1  2.3
± 56* 492 ± 41* 502 ± 54* 287  29
4 2 0
5 4 0
3 2 0
0 0 0
0 1 0
1 1 0
4 3 0
1 1 0
1 0 1
1 0 11
2.8 7.5  2.2 7.7  3.3 7.6  1.9
 48 167  55 171  46 188  52
 6.5 20.9  3.7 21.0  4.2 19.5  4.7
onse; LARZ late asthmatic response; DLARZ dual late asthmatic
sZ mean  SD; Statistical significance as compared with healthy
A (phorbol 12-myristate 13-acetate) (mean  SEM).
pheral blood mononuclear cells (PBMC) with PMA (mean  SEM).
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Table 2 Allergens producing particular types of asthmatic response.
Allergen Standard
concentrations
BU/mL (i.c./BPT)
DYAR NAR
Positive skin response (n Z 22) DYAR (n Z 22) Positive skin response (n Z 31) NAR (n Z 31)
ISR LSR DYSR Total ISR LSR DYSR Total
1:5/1:1 1:5/1:1 1:5/1:1 1:10/1:1 Total 1:5/1:1 1:5/1:1 1:5/1:1 1:10/1:1 Total
Dermatophagoides
pteronyssinus
100/1000 0/1 0/1 1/1 4 1/3 4 1/1 0/1 0/1 3 0/0 3
Dermatophagoides
farinae
100/1000 0/0 1/0 0/0 1 1/e 1 0/0 0/1 0/1 2 0/0 2
Animal danders
-dog 300/3000 0/0 0/0 0/1 1 0/1 1 0/1 0/0 0/1 2 0/0 2
-cat 100/1000 0/1 0/0 1/0 2 1/1 2 1/1 0/1 0/1 4 0/0 4
-horse 200/2000 0/0 0/0 0/1 1 0/1 1
-hamster 200/2000 1/0 0/0 0/0 1 0/1 1
Aspergillus
fumigatus
100/1000 0/0 0/1 0/0 1 0/1 1
Pollen
-grass mix I 100/1000 1/1 0/0 1/2 5 1/4 5 1/2 0/1 0/3 7 0/0 7
-grass mix II 100/1000 0/1 0/0 0/0 1 0/1 1 0/1 0/1 0/0 2 0/0 2
-tree mix 300/3000 0/1 0/0 0/0 1 0/1 1 0/2 0/0 0/1 3 0/0 3
-weed mix 100/1000 0/0 0/0 0/1 1 0/1 1 0/1 0/1 0/0 2 0/0 2
-birch 100/1000 0/1 0/0 0/0 1 0/1 1 1/1 0/1 0/2 5 0/0 5
-poplar 200/2000 0/1 0/0 0/0 1 0/1 1 0/0 0/0 0/1 1 0/0 1
-ragweed giant 100/1000 0/0 0/0 0/1 1 0/1 1
BU/mL Z biologic units per 1 mL; i.c. Z intracutaneous tests; BPT Z bronchial provocation tests; Dilutions of allergenic extracts: 1:5 with respect to the standard concentration; 1:1
(undiluted standard concentration); e Z not performed; DYAR Z delayed asthmatic response; NAR Z negative asthmatic response; ISR Z immediate skin response; LSR Z late skin
response; DYSR Z delayed skin response.
Grass pollen mix I Z Dactylis glomerata, Lolium perenne, Phleum pratensis, Poa pratensis.
Grass pollen mix II Z Festuca pratensis, Holcus lanatus, Agrostis alba, Anthoxanthum odoratum.
Tree pollen mix Z Betula pendula, Corylus avellana, Juniperus communis, Salix alba.
Weed pollen mix Z Artemisia vulgaris, Plantago lanceolata, Rumex acetosa, Taraxacum officinale.
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Table 3 Pre-challenge chemokine concentrations in the (non-stimulated) serum (pg/mL).
Patients DYAR n Z 22 Control subjects
Asthma patients Healthy subjects
IAR n Z 9 LAR n Z 8 DLAR n Z 5 n Z 12
CCL 1 (I-309) <7.8 <7.8 8.9  0.5 <7.8 <7.8
CCL 2 (MCP-1) 38.7  1.5 41.6  2.5 44.8  1.9 43.4  2.0 37.5  1.3
CCL 3 (MIP-1a) 7.4  0.2 8.3  0.7 7.9  0.5 9.0  1.4 8.1  0.6
CCL 4 (MIP-1b) 5.8  1.0 9.5  2.0 8.4  1.1 7.5  0.8 6.9  2.1
CCL 5 (RANTES) 8.5  2.3 10.3  2.6 6.6  1.7 8.0  0.5 7.0  1.9
CCL 7 (MCP-3) 9.0  0.5 12.9  3.1 14.7  2.2* 14.1  1.6 10.5  2.0
CCL 11 (Eotaxin-1) 8.9  1.7 16.7  1.4* 15.9  1.8 16.3  1.0* 8.4  0.5
CCL 13 (MCP-4) 96.3  16 123.5  16 138.1  19* 111.9  8.6 73.2  5.1
CCL 17 (TARC) 65.2  4.9 89.3  6.7* 70.8  4.4 91.3  3.9* 54.5  3.2
CCL 18 (PARC) 25.0  3.4 33.0  1.6 41.2  2.9 40.6  1.1 31.3  2.4
CCL 19 (MIP-3b) 11.5  2.9 9.5  1.3 14.8  2.4 14.3  1.0 10.5  0.7
CCL 20 (MIP-3a) 18.7  3.3* 3.4  0.5 7.9  1.1 8.2  2.5 9.3  3.2
CCL 22 (MDC) 224.3  36 279.0  22 325.4  17* 312.6  15* 219.0  8.8
CCL 23 (MIP-3) 78.2  5.1 69.2  5.7 73.4  3.5 84.2  2.9 61.0  1.4
CCL 24 (Eotaxin-2) 129.8  14. 177.1  12* 154.6  15 168.9  13* 109.2  4.8
CCL 25 (TECK) <62.5 * 84.7  6.3 95.1  2.7 101.3  9.4 85.9  2.6
CCL 26 (Eotaxin-3) 173.4  13 256.3  27* 251.0  13* 263.6  31* 154.2  10
CCL 27 (CTACK) 335.2  29 311.0  36 339.5  29 324.7  25 322.1  18
CXCL 1 (GRO-a) 61.8  9.4* 39.4  3.0 42.7  2.1 43.0  3.3 35.1  1.6
CXCL 8 (IL-8) 9.1  2.0 7.4  1.0 12.8  1.5* 10.5  1.1 5.9  0.4
CXCL 9 (MIG) 25.0  4.3 * 16.8  2.3 16.2  0.7 17.5  1.0 14.9  0.8
CXCL 10 (IP-10) 14.8  3.1 11.3  0.7 10.8  1.0 10.0  0.6 9.4  0.5
CXCL 11 (I-TAC) 54.6  5.7* 43.5  3.6 39.8  1.5 41.2  0.7 34.3  1.1
Values Z mean  SEM; Statistical significance as compared with healthy subject values: *pZ < 0.05.T
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Delayed asthmatic response and chemokines 51concentrations of 500BU/mL for skin prick tests (SPT), 20-300
BU/mL for intracutaneous tests (i.c.) and 100e3000 BU/mL
for BPTs (Table 2). Concentrations recommended by the
manufacturer were up to 500 BU/mL for the skin tests and up
to 5000 BU/mL for the BPTs.
Skin tests
The SPTs have been performed in concentrations of 500 BU/
mL and evaluated after 20 min. The following i.c. tests
were carried out in concentrations of 20e60 BU/mL and
100e300 BU/mL and evaluated 20 min and then 6, 12, 24,
36, 48, 72, and if necessary 96, hours after the intradermal
injection (Table 2). PBS was used as a negative and hista-
mine diphosphate (0.1 and 0.01 mg/mL) as a positive
control. Generally, the skin “wheal and flare” reactions
were always evaluated. A skin wheal reaction (>7.0 mm in
diameter) occurring 20 min after the intradermal injection
was qualified as positive immediate skin response, skin
infiltration appearing between 6 and 12 h as a late skin
response and skin induration recorded later than 48 h was
considered a delayed skin response.16,17,29e32
Bronchial provocation tests (BPT)
The BPTs were performed by means of spirometry (Spiro-
graph D-75 Lode, Groningen, The Netherlands) recording
the FVC and FEV1 values. The aerosolized allergen extracts
and PBS were inhaled using Wiebadener Doppel-Inhalator
at an airflow of 10 L/min. The nebulizer output was
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A0.12e0.14 mL/min and the aerosol particles were of
a median mass diameter of 2.8e3.6 m. The BPTs, being
a modification of the European standard technique,34 were
performed by means of serial dilutions (Table 2) according
to the following schedule: (1) initial (baseline) values
recorded at 0, 5 and 10 min; (2) PBS control values recorded
at 0, 5 and 10 min after a 10-min PBS inhalation; (3) inha-
lation of allergen aerosol for 2  5 min, with inserted
spirometry measurement, followed by the recording of the
FEV1 and FVC values at 0, 5, 10, 20, 30, 45, 60, 90 and
120 min and then every hour up to 12th hour, every second
hour during the 22nd to 38th, the 46th to 62nd and at
the72nd hour interval.16,17,29e32 The PBS control challenge
was performed by the same schedule as that of the BPTs
with allergens.
Supplementary parameters
The IFN-g/IL-4 ratio (%)values in peripheral blood, indi-
cating the Th1/Th2 ratio, were determined by means of
flow-cytometry. The intracellular IFN-g and IL-4 were
estimated in the peripheral blood mononuclear cells
(PBMC) stimulated with Phorbol 12-myristate 13-acetate
(PMA) by means of an enzyme-linked immunoassay (ELISA)
kit,29 are presented in the on-line supplement.
Determination of chemokines in the serum
Samples of venous blood (4 mL)were kept for 1 h at room
temperature and then centrifuged at 3000 g at 4 C for
C
Table 4 Cell counts and Th1/Th2 ratio in peripheral blood and intracellular IFN-g and IL-4 during the DYAR and PBS.
Patients
n Z 22
Before
the
challenge
After the challenge (hrs)
1 6 12 24 36 48 56 72
Leukocytesa
-DYAR 8.3  0.8 9.5  0.4 10.5  0.9 11.0  1.4 12.5  0.9 13.4 ± 0.5* 12.9 ± 0.3* 10.3  0.4 10.1  0.6
-PBS 8.0  0.2 7.9  1.0 7.3  0.1 8.6  0.7 8.2  0.7 8.1  1.0 9.1  0.5 8.2  0.8 8.0  0.3
Eosinophilsb
-DYAR 293  22 334  29 307  21 316  19 284  20 269  15 278  30 241  51 286  25
-PBS 279  26 288  34 297  28 289  30 276  27 268  22 273  20 266  28 279  19
Neutrophilsc
-DYAR 6.9  0.5 6.9  0.8 7.5  0.4 9.3 ± 0.8* 9.5 ± 0.7* 9.8 ± 0.6* 8.5 ± 0.2* 7.0  0.9 6.8  0.3
-PBS 5.9  1.1 6.2  0.5 6.6  0.7 7.1  0.8 6.9  0.4 7.2  0.3 6.8  0.7 6.3  0.8 6.4  0.5
Thrombocytesd
-DYAR 318  33 351  27 336  30 349  31 338  34 427  35 396  25 322  29 317  24
-PBS 289  26 337  20 328  22 275  17 316  23 338  30 336  21 295  33 275  15
Differential countse
Zbasophils
-DYAR 0.07 0.09 0.11 0.09 0.10 0.08 0.06 0.06 0.10
-PBS 0.09 0.11 0.08 0.05 0.08 0.09 0.05 0.07 0.05
Zeosinophils
-DYAR 0.30 0.52 0.40 0.5 0.4 0.52 0.35 0.4 1 0.28
-PBS 0.25 0.30 0.52 0.35 0.25 0.40 0.25 0.30 0.25
Zneutrophils
-DYAR 6.7 6.9 7.7 7.4 9.3* 9.9* 8.6* 8.9* 7.3
-PBS 6.4 6.5 6.7 5.9 6.3 6.5 5.8 7.2 6.4
Zmonocytes
-DYAR 0.4 0.7 1.2 1.7* 2.0* 1.9* 1.0 0.8 0.5
-PBS 0.2 0.4 0.9 0.5 0.8 0.7 05 0.2 0.3
Zlymphocytes
-DYAR 3.1 3.0 2.9 3.4 4.7* 4.8* 4.3* 2.8 2.5
-PBS 2.5 2.2 3.4 3.5 2.9 2.7 2.5 2.6 2.7
Th1/Th2 ratio (%)
f
-DYAR 8.0  1.5 8.9  2.1 9.9  3.0 14.1 ± 4.0* 15.0 ± 4.0* 16.5 ± 3.1* 16.2 ± 3.4* 15.0 ± 3.5* 9.0  3.3
-PBS 7.5  3.2 8.0  2.1 9.3  2.0 7.9  2.4 8.3  3.6 8.7  2.5 9.0  2.5 8.1  2.3 7.7  2.6
IFN-g (pg/mL)g
-DYAR 207  99 190  86 227  105 264  109 367 ± 102* 436 ± 107* 400 ± 91* 365 ± 113* 248  79
-PBS 193  75 211  84 221  100 205  98 209  103 194  110 192  86 195  100 177  88
IL-4 (pg/mL)g
-DYAR 20.9  2.0 23.6  3.3 25.1  2.0 30.8  3.9 27.4  3.5 26.0  2.9 24.2  2.8 25.7  3.4 26.3  3.5
-PBS 22.5  4.1 26.0  2.9 30.7  3.1 28.6  2.5 29.1  2.4 26.5  3.1 23.8  3.2 25.0  2.3 23.6  2.9
ValuesZmean  SD; Statistical significance as compared with healthy subject values: *Z p < 0.05 (in bold), PBSZ phosphate buffered
saline.
a Normal value 4.0e10.0  109/L.
b Normal value < 300  106/L.
c Normal value 2.0e7.2  109/L.
d Normal value 150e400  109/L.
e Normal values (109/L): B Z <0.2; E Z <0.50; N Z 2.0e7.2; M Z 0.2e1.0; L Z 1.0e4.0  109/L.
f Determined by means of flow-cytometry after stimulation with PMA (phorbol 12-myristate 13-acetate) (means  SEM).
g Determined by means of ELISA after “in vitro” stimulation of mononuclear cells (PBMC) with PMA (means  SEM).
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52 Z. Pelikan10 min. The serum aliquots were stored at 70 C until
analysis. The chemokines were determined by means
of commercial enzyme-linked immunoassay (ELISA, EIA)
kits (R & D System, Minneapolis/MN, USA), according to
the manufacturers’ recommendations, by a double-blind
schedule. All measurements were performed in dupli-
cate. The minimal detection limits of the ELISA kits, in pg/
mL, were as follows: CCL 1 (7.8), CCL 2 (5.0), CCL 3 (7.0),
R
ECCL 4 (4.0), CCL 5 (5.0), CCL 7(7.8), CCL 11 (5.0), CCL 13
(7.8), CCL 17 (7.0), CCL 18 (8.0), CCL 19 (0.87), CCL 20
(0.87), CCL 22 (62.5), CCL 23 (15.0), CCL 24 (2.5), CCL 25
(62.5), CCL 26 (2.3), CCL 27 (1.6), CXCL 1 (5.0), CXCL 8
(3.5), CXCL 9 (3.8), CXCL 10 (1.7), CXCL 11 (3.0). The inter-
assay coefficients of variations for these kits were less than
9%, whereas the intra-assay coefficients of variations were
less than 8%.
Delayed asthmatic response and chemokines 53Statistical analysis
The initial and repeated DYAR and PBS controls were
analyzed by means of fitting polynomials to the mean
curves over time, eight time points within 120 min and
twenty-five time points up to 72 h after the allergen or PBS
challenge. The hypotheses were tested by the generalized
multivariate analysis of the variance model (MANOVA).35
The course of concentration changes of particular che-
mokines in blood during the DYAR and PBS controls has also
been analyzed by means of the MANOVA method.35
The pre-challenge serum concentrations of particular
chemokines measured both in the individual DYAR patients
and their mean values calculated also for all patients within
the same group were compared with the mean concentra-
tion values of the corresponding chemokines measured in
the healthy control subjects and statistically evaluated by
means of a Wilcoxon matched-pair signed rank test.
The individual post-challenge values of particular che-
mokines recorded at each of the time points during the
repeated DYAR and PBS control in each of the patients were
compared with their pre-challenge value and additionally
evaluated by Wilcoxon matched-pair signed rank test. The
single post-challenge chemokine values measured at each
of the time points during the repeated DYAR were
compared with the corresponding post-challenge PBS
values and additionally evaluated by ManneWhitney U test.
The mean concentration values of particular chemokines
recorded singly in patients of the control groups (IAR, LAR,
DLAR) were compared with the mean values of chemokines
measured singly in control healthy subjects and evaluated
by Wilcoxon matched-pair rank test (Table 3). A P < 0.05
was considered to be statistically significant value for all
above mentioned tests.Results
The isolated form of DYAR recorded in 22 patients, begin-
ning within 26e32 h, reaching maximum within 32e48 h and
resolving within 56 h after the allergen challenge (Fig.1),
was statistically highly significant both in comparison of the
post-challenge with the pre-challenge FEV1 values
(p < 0.001) and as compared with the PBS control values
(p < 0.001).
The repeated DYAR was also highly significant both
comparing the post-challenge with the pre-challenge FEV1
values (p < 0.001) and as compared with the PBS controls
(p<0.001) (Fig.1).Nostatistically significantdifferenceswere
found between the initial and the repeated DYAR (p> 0.1). No
significant differences were found in the appearance of DYAR
with respect to the individual allergens (p> 0.1) (Table 2). No
significant differences in the post-challenge FEV1 values, with
respect to the pre-challenge FEV1 values, were recorded
during the initial aswell as the repeatedPBScontrol challenges
(p > 0.05, p > 0.1, respectively).
The DYAR patients demonstrated allergen-relevant
positive immediate skin response in 41%(n Z 9), late skin
response in 14 (n Z 3) and delayed skin response in 45%
(n Z 10), decreased bronchial histamine threshold in 78%
(Table 1) and non-increased immunoglobulin concentra-
tions in the serum.
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cyte, neutrophil and lymphocyte counts, significant
changes in the Th1/Th2 cell ratio in peripheral blood in
favor of Th1 cells (p < 0.01), significant increase in the
intracellular concentration of IFN-g (p < 0.05), but not of
IL-4 (p > 0.05) (Table 4).
In DYAR patients, the pre-challenge serum concentra-
tions of CCL 20, CXCL 1, CXCL 9 and CXCL 11 were slightly
elevated, whereas concentration of CCL 25 was slightly
decreased, as compared with the healthy control subjects.
No statistically significant differences have been found in
the pre-challenge concentrations of other chemokines
between the DYAR patients and the healthy control
subjects (p > 0.05) (Table 3).
The DYAR was associated with significant changes
(p < 0.05) in the serum concentrations, of the following
chemokines (Table 5): (a)an increased serum concentration
of CCL 2 at 6, 12 and 24 h (followed by its decrease at 48 h),
CCL 3 at 6, 12, 24 and 36 h, CCL 4 at 6, 12, 24, 36 and 48 h,
CCL 7 at 12, 24 and 36 h, CCL 20 at 1 and 6 h, CXCL 1 at 1
and 6 h, CXCL 8 at12, 24 and 36 h, CXCL 9 at 1, 6, 12 and
24 h (followed by its decrease at 48 and 56 h), CXCL 10 at
24, 36 and 48 h, and CXCL 11 at 1, 6 and 12 h; (b)
a decreased serum concentration of CCL 5 at 6, 12 and 24 h,
CCL 11 at 6, 12, 24 and 36 h, CCL 17 at 6, 12 and 24 h, CCL
22 at 6, 12 and 24 h, CCL 24 at 1, 6 and 12 h, and CCL 26 at 6
and 12 h, as compared both with their pre-challenge values
and with the PBS control values. No significant changes in
the serum concentrations of chemokines were measured
during PBS control challenge (p > 0.1) (Table 5).
Control subjects
The pre-challenge serum concentrations of some chemo-
kines measured in the control patients with IAR, LAR and
DLAR differed from those recorded in the healthy control
subjects (Table 3).
Discussion
The DYAR, an unique asthmatic response phenotype,
recorded in approximately 12% patients with allergic
bronchial asthma,29 differs from the other types of asth-
matic response, such as IAR and LAR, not only with respect
to its clinical features including the clinical course, but also
in its association with other “in vivo” and “in vitro” diag-
nostic parameters, in the immunologic features and in
association with changes of various factors in blood (Table
1).12,16e32,36e39
Results of our previous studies demonstrated association
of DYAR with significantly increased plasma concentrations
of LTB4 and MPO,
31 adhesion molecules, especially sICAM-1,
sVCAM-1, sPECAM-1, sE- and L-selectin,30 and of some
cytokines, such as IFN-g, IL-2, IL-18, G-CSF, TNF-a, TGF-b,
decreased plasma concentrations of IL-7 and IL-12p70. The
concentrations of the other cytokines, especially IL-1b, IL-
4, IL-5, IL-6, IL-8, IL-12p40 and GM-CSF did not change
significantly.32
The DYAR was also accompanied by changes in the Th1/
Th2 ratio, in favor of Th1 cells,
29e32 and increased intra-
cellular concentrations of IFNg and IL-2, but not IL-4 or IL-
C
TE
D
Table 5 Concentrations of particular chemokines in pg/mL (mean  SEM) recorded during DYARs and PBS control tests.
Patients
N Z 22
Before the
challenge
After the challenge (hrs)
1 6 12 24 36 48 56 72
CCL 1 (I-309)
-DYAR <7.8 <7.8 <7.8 <7.8 8.5  0.4 8.2  0.3 <7.8 <7.8 <7.8
-PBS <7.8 <7.8 <7.8 <7.8 <7.8 <7.8 <7.8 <7.8 <7.8
CCL 2 (MCP-1)
-DYAR 30.2  1.6 28.9  2.1 57.5 ± 3.9* 84.1 ± 2.7* 93.0 ± 4.5* 11.3  1.4 <5.0* 9.2  0.8 27.0  1.0
-PBS 33.5  0.4 31.0  1.3 35.2  1.7 32.3  2.2 34.7  3.1 30.9  2.1 33.05  1.8 28.4  0.9 31.2  1.7
CCL 3 (MIP-1a)
-DYAR 8.5  0.3 9.8  1.0 28.6 ± 2.1* 41.7 ± 2.9* 48.3 ± 3.4* 27.9 ± 1.3* 12.4  0.7 <7.0 8.4  0.5
-PBS 8.2  0.5 8.7  0.6 9.5  1.0 9.2  0.4 9.8  1.1 8.6  0.9 9.3  1.0 10.2  1.3 8.0  0.6
CCL 4 (MIP-1b)
-DYAR 6.6  0.2 5.9  0.5 7.4  2.8 29.0 ± 3.1* 25.5 ± 2.0* 19.4 ± 2.2* 18.7 ± 1.3* 9.0  0.2 6.8  0.4
-PBS 7.0  1.0 7.2  0.6 8.5  1.1 5.9  0.3 5.7  0.6 6.6  1.0 7.4  0.9 7.1  0.8 7.1  2.3
CCL 5 (RANTES)
-DYAR 15.7  2.3 17.9  1.5 <5.0* <5.0* <5.0* 7.8  1.3 14.9  2.0 16.5  1.7 16.1  0.9
-PBS 13.9  1.2 15.3  0.8 14.6  2.0 14.1  1.7 15.0  1.4 15.5  0.7 13.6  1.1 14.4  1.3 14.9  1.2
CCL 7 (MCP-3)
-DYAR 9.4  0.3 10.1  1.0 10.7  1.8 20.5 ± 0.6* 39.6 ± 0.3* 35.9 ± 1.0* 12.1  0.7 11.0  2.1 10.2  1.3
-PBS 9.6  0.8 11.0  0.5 10.2  0.4 9.1  0.2 8.5  0.7 10.8  0.6 10.0  0.9 10.3  1.0 9.0  0.8
CCL 11 (Eotaxin-1)
-DYAR 7.7  2.1 7.2  1.0 <5.0* <5.0* <5.0* <5.0* 5.3  0.2 6.8  1.0 7.1  2.0
-PBS 7.8  1.2 8.0  1.7 8.1  1.0 7.2  0.4 7.9  0.6 8.0  1.5 7.5  1.7 7.2  0.5 8.0  1.0
CCL 13 (MCP-4)
-DYAR 112.3  4.1 105.1  4.6 92.0  3.2 98.4  2.9 107.8  3.5 95.0  2.7 109.3  5.1 88.5  3.4 96.9  3.0
-PBS 89.8  3.2 93.9  2.8 106.5  1.7 101.3  2.4 96.1  1.2 103.3  2.2 90.9  1.7 93.5  2.0 91.4  0.8
CCL 17 (TARC)
-DYAR 68.3  3.5 54.9  4.1 <7.0* <7.0* <7.0* 47.5  5.9 56.8  4.2 65.5  3.8 63.0  2.7
-PBS 71.5  5.6 61.8  4.9 58.4  3.3 61.6  2.5 70.2  1.9 66.4  1.5 69.0  3.7 62.0  2.3 67.5  1.6
CCL 18 (PARC)
-DYAR 31.6  4.8 38.0  4.2 29.7  3.0 25.9  2.2 36.4  2.8 30.0  3.7 28.9  1.6 32.0  2.9 34.2  1.5
-PBS 28.8  3.0 30.5  2.6 31.3  2.1 29.7  1.5 25.3  1.0 34.8  4.0 30.3  2.5 26.6  1.7 30.9  2.0
CCL 19 (MIP-3b)
-DYAR 12.7  1.5 14.7  3.4 11.2  2.5 13.8  3.9 12.2  1.3 12.9  2.2 10.8  1.5 11.3  1.9 11.7  1.4
-PBS 10.9  0.8 10.5  1.7 12.7  3.1 11.3  1.8 10.8  2.2 11.0  1.4 11.5  0.7 10.8  3.0 11.2  1.1
CCL 20 (MIP-3a)
-DYAR 19.5  0.6 38.7 ± 3.5* 46.9 ± 2.7* 22.1  1.3 20.8  2.0 23.9  2.5 18.4  1.0 17.2  2.3 18.8  1.6
-PBS 21.4  3.0 25.5  2.9 22.0  1.1 23.8  2.4 24.5  1.3 25.6  1.9 20.0  1.7 21.2  1.5 20.9  2.0
CCL 22 (MDC)
-DYAR 237.2  21 225.3  18 73.8 ± 12* <62.5* 85.9 ± 31* 219.4  26 208.5  31 229.2  25 216.8  15
-PBS 211.0  14 203.1  15 234.6  24 223.8  29 235.2  20 216.9  18 242.0  27 236.5  17 228.5  23
CCL 23 (MIP-3)
-DYAR 83.4  6.9 75.2  5.4 91.7  4.9 86.5  3.8 79.0  6.1 82.0  3.9 90.0  4.4 66.7  5.2 77.9  3.8
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-PBS 70.8  3.3 62.5  2.9 80.3  3.4 75.8  2.5 84.0  4.3 73.7  2.5 84.2  3.1 73.0  3.9 71.8  2.3
CCL 24 (Eotaxin-2)
-DYAR 135.0  11 51.7 ± 4.8* 43.2 ± 3.9* 47.4 ± 5.3* 105.2  7.2 128.5  4.9 133.0  3.6 127.5  2.8 131.0  4.2
-PBS 144.2  8.7 141.0  6.5 133.9  5.1 140.0  6.1 132.7  5.5 125.0  7.3 129.5  4.0 138.0  3.5 142.3  2.7
CCL 25 (TECK)
-DYAR <62.5 <62.5 <62.5 <62.5 <62.5 <62.5 76.1  3.6 75.8  4.0 <62.5
-PBS <62.5 <62.5 <62.5 <62.5 <62.5 <62.5 <62.5 <62.5 <62.5
CCL 26 (Eotaxin-3)
-DYAR 182.0  12 104.5  9.0 71.9 ± 6.8* 80.3 ± 5.9* 156.5  8.0 167.3  10 177.0  12 169.5  8.8 175.4  9.3
-PBS 165.3  9.1 155.0  8.7 168.3  11 174.6  15 169.5  9.4 181.2  13 156.4  9.9 158.0  12 172.3  8.0
CCL 27 (CTACK)
-DYAR 361.5  34 320.1  28 316.4  19 353.0  26 347.9  31 330.8  25 329.6  18 355.0  25 344.6  14
-PBS 327.0  13 345.5  23 302.7  10 318.6  13 329.5  11 348.0  14 335.9  31 341.0  22 353.3  9.2
CXCL 1 (GRO-a)
-DYAR 65.0  7.2 189.4 ± 6.3* 214.5 ± 8.8* 102.7  5.4 73.2  4.8 51.3  2.7 55.0  1.9 59.4  1.5 61.2  2.4
-PBS 63.8  5.1 59.0  4.8 52.9  2.5 61.6  4.9 58.3  3.5 60.0  1.9 53.3  2.5 62.5  2.1 67.0  3.5
CXCL 8 (IL-8)
-DYAR 8.1  1.3 7.4  2.0 14.5  3.1 29.4 ± 4.3* 25.9 ± 3.6* 21.0 ± 2.8* 10.4  1.0 <3.5* 7.3  0.9
-PBS 7.7  0.6 8.9  3.2 6.8  1.5 7.2  0.5 8.3  2.4 9.5  3.0 8.2  0.9 7.5  0.6 7.8  1.3
CXCL 9 (MIG)
-DYAR 22.4  0.5 83.6 ± 3.7* 98.0 ± 4.9* 75.8 ± 5.1* 69.6 ± 3.5* 34.0  4.6 7.5 ± 2.9* 6.1 ± 1.8* 18.4  0.8
-PBS 20.8  1.0 25.5  2.4 30.0  2.2 23.6  1.5 27.0  2.5 22.1  1.9 24.7  1.3 25.0  1.4 21.5  1.6
CXCL 10 (IP-10)
-DYAR 15.4  2.3 13.8  1.9 12.6  1.2 18.7  2.5 39.4 ± 3.1* 41.9 ± 2.8* 37.2 ± 1.5* 19.4  2.2 17.1  1.3
-PBS 15.9  1.5 11.6.0.7 14.3  2.1 10.5  0.8 13.7  1.1 12.6  1.9 15.9  2.4 16.3  1.5 16.1  2.0
CXCL 11 (I-TAC)
-DYAR 51.2  4.3 96.5 ± 4.2* 109.8 ± 5.4* 119.0 ± 3.7* 66.8  3.5 59.0  3.4 63.0  2.9 55.1  3.3 56.7  2.8
-PBS 49.0  2.2 52.3  1.7 54.9  3.5 58.8  1.4 54.0  2.3 46.7  1.5 48.2  3.4 50.5  2.8 48.1  1.3
Values Z mean  SEM; Statistical significance as compared with the pre-challenge (baseline) values: * Z p < 0.05 (in bold); PBS Z phosphate buffered saline.
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56 Z. Pelikan5, in blood lymphocytes.29 The significantly increased
plasma concentrations of TGF-b and a slightly increased
serum concentration of IL-10, might be suggestive for
a possible involvement of the Th3 ecells in the mechanism
underlying the DYAR.32 A possible role of another important
T-helper cell sub-set, the Th 17 cells producing IL-17 A-F, in
the mechanism(s) leading to the DYAR, has not yet been
investigated by us for technical reasons. The increased
counts of total leukocytes, neutrophils and monocytes, but
not those of eosinophils, accompanying the DYAR,29e32 is
partly consistent with the other investigators’ findings of
a separate entity, the “non-eosihophilic/neutrophilic”
asthma phenotype.40e50.
Chemokines represent a very important part of immuno-
logic mechanisms and processes.6e9,11e15,19e22,28,38,39,51e58
They act predominantly as chemoattractants and signal
transmitters among various cell types, but they also display a
number of other effects, such as stimulation/activation
vs inhibition effects on various intra- and extracellular
processes and cellular traffic, affecting the maturation
and differentiation period of various cell line-
ages.6e9,11,13,38,54e57 They operate in a close relation with
other factors participating in the immunologic mechanisms,
such as classical mediators, cytokines, cell surface mole-
cules (CD), adhesion molecules and cellular constituents
released by various cell types.2,3,5e9,11,13,15,20,38,39,51e57
Most of their effects are realized through the interaction
with their ligands, which are specific receptors expressed on
the target cells.5e9,11e15,19,20,39,51,52,54,56,57 The role of
chemokines in allergic bronchial asthma has been studied
from various points of view.2,5e8,11,12,14,15,19e22,36,38,51,53,55
In most of these studies the chemokines were determined
by means of a single measurement in bronchial asthma
patients.2,14,15,51,53 In some of these studies the chemokines
were measured in bronchial lavage (BAL) fluid, sputum or
bronchial biopsies following. the segmental/intrabronchial
challenge with allergen5,12,20e22,38 The papers dealing with
the measurement of the chemokine concentration changes
in blood during the individual types of asthmatic response to
allergen challenge are not numerous.12 Moreover, in some
studies the chemokine concentrations were measured after
“in vitro” stimulation of the cells isolated from peripheral
blood, induced sputum or BAL fluid.38
A single determination of the concentrations of immu-
nologic factors, such as chemokines, in the peripheral
blood, sputum or BAL fluid in asthmatics related only to
a certain time point and not to a specific and controlled
event, such as provocation test with allergen, does not
generate information on the dynamic course of the che-
mokine changes during the whole immunologic process and
clinical response. This can only be achieved by measure-
ments of these factors before and repeatedly after the
bronchial or segmental provocation tests with allergen,
techniques by which the concentration changes of
particular factors, e.g. chemokines, in blood or in BAL
fluid can be related to a certain type of asthmatic
response.5,12,20e22,38
The bronchial challenge techniques have a number of
advantages and disadvantages. The advantage of the
segmental challenge is the provocation of a limited lung
area with a small allergen amount and direct access to the
immunologic reaction site. Its disadvantage is an exclusion
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Aof the large part of the respiratory system (from the mouth
to the secondary bronchi) which may regularly be the site
of the initial stages of the immunologic process leading to
the asthmatic response. This method is relatively laborious,
requires application of an anesthetic agent and the less
natural BAL technique can be a burden for the patient. The
advantage of the inhalation technique is its simulation of
the natural allergen exposure upon including of all parts of
the airways, relatively low strain for the patient and low
risk of post-intervention complications besides the ex-
pected bronchoconstriction. Its disadvantage is the need of
a rather large effective allergen dose.16,17,29e32,59,60
Generally, there is a dearth of data concerning the
appearance and concentration changes of chemokines in
the peripheral blood during the particular types of asth-
matic response due to the inhalational bronchial provoca-
tion with allergen (BPT). Moreover, there is also a scarcity
of comprehensive information concerning the chemokine
profiles in peripheral blood, sputum and BAL fluid, in
healthy subjects which could be used as reference
values.58
The changes in chemokine concentrations during the
DYAR due to bronchial challenge with allergen in patients
with allergic bronchial asthma have not yet been investi-
gated. Our current study, being probably the first one on
this topic, presents a number of interesting and unique
data. These results concerning the chemokine profile
associated with the DYAR differ distinctly from the che-
mokine profiles found by other investigators in patients
developing either the IAR or the LAR.5,12,20e22,38,55 The
different chemokine profiles would be suggestive for
involvement of different immunologic mechanisms in the
DYAR on one hand and in the IAR and LAR on the other hand.
One of the remarkable clinical features recorded in
patients developing the DYAR was appearance of various
types of skin response, such as immediate late and delayed,
to the same allergens as those causing the positive DYAR
(Table 1). Unfortunately, we have not yet a satisfactory
explanation for this variation in skin tests. Perhaps, it may
be related to some differences in the immunologic system
of the skin and that of the airways, and to different pro-
cessing of the allergens on these different locations.
Another interesting finding was the non-increased serum
concentrations of the immunoglobulins, especially of the
allergen-specific IgE, in the DYAR patients, whereas in
asthmatics of the 3 control groups (IAR, LAR, DLAR) the
positive allergen-specific IgE antibodies were found.
Regarding these findings, similar to our previous
results,29,30,32 the involvement of the IgE-mediated hyper-
sensitivity in the mechanism(s)underlying the DYAR seems
to be unlikely.
The pre-challenge serum values of some chemokines
recorded in the DYAR patients differed slightly from those
measured in control healthy subjects (Table 3). The pre-
challenge serum values of some chemokines measured in
the control patients exhibiting IAR, LAR or DLAR were also
slightly increased as compared with the values recorded in
the healthy control subjects (Table 3). These findings are
partly consistent with other investigators’ data of increased
levels of CCL 11, CCL 13, CCL 20, CCL 22, CCL 24, CCL 26,
CXCL 8 in the serum2,12,61e63 or CCL 11, CCL 22, CCL 24, CCL
26, CXCL 8 in the BAL fluid of asthmatics.5,12,21,53,62
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Delayed asthmatic response and chemokines 57In contrast, the post-challenge chemokine profiles
recorded in the serum during the DYAR were characterized
by the significantly increased concentrations of CCL 2, CCL
3, CCL 4, CCL 7, CCL 20, CXCL 1, CXCL 8, CXCL 9, CXCL 10
and CXCL 11, significantly decreased concentrations of CCL
5, CCL 11, CCL 17, CCL 22, CCL 24 and CCL 26, and non-
altered levels of CCL 1, CCL 13, CCL 18, CCL 19, CCL 23, CCL
25 and CCL 27.
These results, together with significantly increased
counts of total leukocytes, neutrophils, lymphocytes and
monocytes, but not of eosinophils, absence of allergen-
specific IgE antibodies in the serum, unchanged concen-
trations of other immunoglobulins, changes of Th1/Th2 ratio
in favor of Th1 ecells, and increased concentration of
intracellular IFN-g but not that of IL-4, in PBMC, together
with our previous findings29e32, would suggest possible
involvement of the cell-mediated hypersensitivity, upon
participation of Th1 lymphocytes, neutrophils, monocytes,
epithelial and endothelial cells, and probably also NK,
macrophages and dendritic cells, in the mechanisms
underlying the DYAR.
Unfortunately, no reliable data concerning the other T
cell subsets, such as Th 17 and Treg and their products as
well as the activation degree and other features of the
particular chemokine membrane receptors on the various
cell types in relation to the DYAR, are available. Moreover,
the cytologic and immunologic features in BAL fluid during
the DYAR have not yet been studied.29e32 These facts may
be regarded as a certain deficit of the current study and
they have to be certainly investigated in the following
studies.
It can be summarized that, the DYAR, a relatively unique
asthmatic response phenotype, displays a number of
remarkable clinical and immunologic features,29e32 such as
(a) clinical manifestation within 26e56 h after the allergen
exposure, (b) clinical symptoms represented predominantly
by pronounced dyspnea; (c) unsatisfactory correlation with
skin prick tests and bronchial histamine threshold; (d)
absence of allergen-specific IgE antibody in the serum and
of blood eosinophilia; (e) increased counts of leukocytes,
neutrophils, monocytes and lymphocytes in peripheral
blood; (f) shifting of the Th1/Th2 ratio in peripheral blood in
favor of the Th1 cells; (g) increased blood concentrations of
IFN-g, IL-2, IL-18, G-CSF, TNF-a, TGF-b, but not of IL-4 or IL-
5; (h) increased blood concentrations of CCL-3,-4,-20, and
CXCL-1,-8,-9,-10 and -11. These facts may indicate
a possible involvement of the cell-mediated hypersensi-
tivity mechanism in the DYAR. Regarding these facts, it
would be very difficult to predict the possible existence of
DYAR from the standard diagnostic procedures performed in
the patients with bronchial asthma and this response type
can therefore be overlooked in the practice. The bronchial
challenge with allergen seems to be only reliable procedure
for detection and definite confirmation of the DYAR.
In conclusion, the results of the current study, together
with our previously published results,29e32 suggest
a possible involvement of the cell-mediated hypersensi-
tivity mechanisms in the DYAR. Nevertheless, further
concurrent clinical and immunologic research, including
BAL, airway biopsy, other chemokines, cytokines, chemo-
kine receptors on the membrane of the circulating as well
as in the bronchial tissue residing cell types, other T-cell
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Asubsets, such as Treg, Th 17, and various transcription
factors, will be needed to clarify exactly the immunologic
mechanism(s) underlying this clinical phenomenon.
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